European Academy of Dermatology and Venereology Congress

European Academy of Dermatology and Venereology Congress

Source:

Armstrong A, et al. ePoster. Deucravacitinib improves psoriasis symptoms and signs diary domain scores in patients with moderate to severe plaque psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 studies. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Armstrong reports receiving grants and personal fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma and Novartis; personal fees from Boehringer Ingelheim/Parexel, Celgene, Dermavant, Genentech, GlaxoSmithKline, Menlo Therapeutics, Merck, Modernizing Medicine, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Science 37, Sun Pharma and Valeant; and grants from Dermira, Kyowa Hakko Kirin and UCB. Please see the poster for all other authors’ relevant financial disclosures.
October 11, 2021
1 min read
Save

Deucravacitinib reduces signs, symptoms of psoriasis

Source:

Armstrong A, et al. ePoster. Deucravacitinib improves psoriasis symptoms and signs diary domain scores in patients with moderate to severe plaque psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 studies. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Armstrong reports receiving grants and personal fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma and Novartis; personal fees from Boehringer Ingelheim/Parexel, Celgene, Dermavant, Genentech, GlaxoSmithKline, Menlo Therapeutics, Merck, Modernizing Medicine, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Science 37, Sun Pharma and Valeant; and grants from Dermira, Kyowa Hakko Kirin and UCB. Please see the poster for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patient-reported psoriasis signs and symptoms improvement was significantly better in those treated with deucravacitinib over placebo and apremilast, according to two clinical trials presented at the EADV Congress virtual meeting.

“Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor that binds to the regulatory domain with high specificity,” April Armstrong, MD, MPH, associate dean for clinical research at the University of Southern California Keck School of Medicine, said in the presentation.

The double-blind, global, phase 3 POETYK PSO-1 and PSO-2 trials compared deucravacitinib to placebo and apremilast over 52 weeks of treatment in patients with moderate to severe psoriasis. Subjects were randomly assigned 2:1:1 to receive deucravacitinib 6 mg once daily, placebo or apremilast 30 mg twice daily.

Physician Global Assessment score improvement and patient-recorded psoriasis symptoms and signs, measured by the Psoriasis Symptoms and Signs Diary (PSSD), were recorded.

The two trials included 666 and 1,020 patients, respectively.

At week 16 PSSD symptom scores had a mean improvement of –32 and –31.3 for the two deucravacitinib groups, compared to –6.3 and –3.2 for the two placebo groups and –23.7 and –23 for the two apremilast groups.

Sign scores had a mean improvement of –34.3 and –35.0 for the deucravacitinib groups, –7.7 and –6.3 for the placebo groups and –25.4 and –26.5 for the apremilast cohorts.

“The greatest symptom improvement was consistently observed for itch, a symptom that is present in the majority of patients with psoriasis and presents a significant burden to quality of life,” Armstrong said. “These patient-reported outcomes for psoriasis symptoms and signs were consistent overall with physicians’ assessments and clinical results.”